[go: up one dir, main page]

ES2100952T3 - Medicamento para tratar adenocarcinoma prostatico. - Google Patents

Medicamento para tratar adenocarcinoma prostatico.

Info

Publication number
ES2100952T3
ES2100952T3 ES91912759T ES91912759T ES2100952T3 ES 2100952 T3 ES2100952 T3 ES 2100952T3 ES 91912759 T ES91912759 T ES 91912759T ES 91912759 T ES91912759 T ES 91912759T ES 2100952 T3 ES2100952 T3 ES 2100952T3
Authority
ES
Spain
Prior art keywords
prostatico
medication
treat adenocarcinoma
adenocarcinoma
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91912759T
Other languages
English (en)
Inventor
Keith Johnson Randall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24173248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2100952(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of ES2100952T3 publication Critical patent/ES2100952T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A UN METODO PARA TRATAR EL ADENOCARCINOMA PROSTATICO HUMANO EMPLEANDO UN COMPUESTO INHIBIDOR DE LA 5-(ALFA)-REDUCTASA ESTEROIDE O UNA COMBINACION DE COMPUESTOS INHIBIDORES DE LA 5-(ALFA)-REDUCTASA ESTEROIDE.
ES91912759T 1990-06-27 1991-06-21 Medicamento para tratar adenocarcinoma prostatico. Expired - Lifetime ES2100952T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/544,709 US5300294A (en) 1990-06-27 1990-06-27 Method of treating prostatic adenocarcinoma

Publications (1)

Publication Number Publication Date
ES2100952T3 true ES2100952T3 (es) 1997-07-01

Family

ID=24173248

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91912759T Expired - Lifetime ES2100952T3 (es) 1990-06-27 1991-06-21 Medicamento para tratar adenocarcinoma prostatico.

Country Status (14)

Country Link
US (2) US5300294A (es)
EP (1) EP0536282B1 (es)
JP (5) JP2702280B2 (es)
KR (1) KR100209825B1 (es)
AT (1) ATE151635T1 (es)
AU (1) AU650033B2 (es)
CA (1) CA2084775C (es)
DE (1) DE69125714T2 (es)
DK (1) DK0536282T3 (es)
ES (1) ES2100952T3 (es)
GR (1) GR3024064T3 (es)
IE (1) IE81134B1 (es)
WO (1) WO1992000010A1 (es)
ZA (1) ZA914919B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5239075A (en) * 1991-08-21 1993-08-24 Eli Lilly And Company Process for the preparation of benzo (f) quinolinones
CA2084799C (en) 1991-12-17 2003-01-28 Glenn J. Gormley Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones
US5994362A (en) * 1992-03-11 1999-11-30 Merck & Co., Inc. Method of treatment for prostatic cancer
US5710275A (en) * 1992-05-20 1998-01-20 Merck & Co., Inc. 7β-substituted-4-aza-5α-androstan-3-ones as 5α-reductase inhibitors
EP0641209A4 (en) * 1992-05-20 1995-08-23 Merck & Co Inc NEW 17-ESTER, AMID AND KETONE DERIVATIVES OF 3-OXO-4-AZASTEROIDS AS 5-ALPHA REDUCTINE INHIBITORS.
GB9210880D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Corp Compounds
GB9213901D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Compounds
US5882681A (en) * 1993-09-03 1999-03-16 Smithkline Beecham Corporation Stabilized tablet formulation
US5763490A (en) * 1994-09-20 1998-06-09 University Of South Carolina Treating prostate cancer with tartrate ions
US5578724A (en) * 1994-09-20 1996-11-26 Eli Lilly And Company Process for preparation of benzo[f]quinolinones
US5635197A (en) * 1995-03-21 1997-06-03 Eli Lilly And Company Treatment and prevention of prostatic cancer metastasis
US5629007A (en) * 1995-03-21 1997-05-13 Eli Lilly And Company Method of preventing prostatic cancer development
JPH09172979A (ja) * 1995-12-27 1997-07-08 Ajinomoto Co Inc 新規リン酸アミノ酸複合塩及び制酸剤を含有する反すう動物用飼料添加組成物
US6093722A (en) 1997-02-26 2000-07-25 Sankyo Company, Limited Method for treating prostate cancer
GB9717444D0 (en) * 1997-08-19 1997-10-22 Glaxo Group Ltd Pharmaceutical composition
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
US6365181B1 (en) 2000-04-20 2002-04-02 Gattefosse Corporation Thixatropic gelatin carrier composition
NZ548670A (en) * 2004-01-28 2010-05-28 Androscience Corp Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
US20060084704A1 (en) * 2004-01-28 2006-04-20 Charles Shih Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
US8710272B2 (en) 2007-01-08 2014-04-29 Androscience Corporation Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
CN101711231B (zh) 2007-01-08 2014-03-12 安德鲁科技有限公司 具有(取代苯基)-丙烯醛部分的化合物、它们的衍生物、生物活性及其用途
US9000222B2 (en) 2007-01-08 2015-04-07 Androscience Corporation Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
EP2175726A4 (en) 2007-07-31 2011-01-05 Androscience Corp COMPOSITIONS WITH ANDROGEN RECEPTOR DERIVATIVES AND METHOD FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF SKIN DISEASES OR HAIR LOSS
US20100048912A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
RU2015137617A (ru) 2013-03-14 2017-04-18 Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер Агенты, подавляющие андрогенные рецепторы, и их применение
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
US10585101B2 (en) 2016-03-10 2020-03-10 Wavesense, Inc. Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
JPS63203625A (ja) * 1987-02-19 1988-08-23 Kao Corp ５α−リダクタ−ゼ阻害剤
EP0285383B1 (en) * 1987-04-03 1994-03-16 Merck & Co. Inc. Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
ZA883034B (en) * 1987-04-29 1989-03-29 Smithkline Beckman Corp Steroid 5-alpha-reductase inhibitors
US5041433A (en) * 1987-04-29 1991-08-20 Smithkline Beecham Corporation 11-keto or hydroxy 3,5-diene steroids as inhibitors of steriod 5-α-reductase
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
US4937237A (en) * 1988-12-23 1990-06-26 Smithkline Beckman Corporation Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase
US4882319A (en) * 1988-12-23 1989-11-21 Smithkline Beckman Corporation Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4970205A (en) * 1988-12-23 1990-11-13 Smithkline Beecham Corporation Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4946834A (en) * 1988-12-23 1990-08-07 Smithkline Beecham Corporation Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
EP0595796B1 (en) * 1989-07-07 2003-01-15 Endorecherche Inc. Method of treatment of androgen-related diseases
CA2023157A1 (en) * 1989-08-21 1991-02-22 Gary H. Rasmusson 17 beta-acyl-4-aza-5 alpha-androst-1-ene-3-ones as 5 alpha-reductase inhibitors
US5032586A (en) * 1989-08-24 1991-07-16 Smithkline Beecham Corporation 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5137882A (en) * 1990-06-11 1992-08-11 Holt Dennis A Steroidal 3-acetic acid derivatives as 5-alpha-reductase inhibitors
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma

Also Published As

Publication number Publication date
KR100209825B1 (ko) 1999-07-15
DE69125714D1 (de) 1997-05-22
EP0536282B1 (en) 1997-04-16
GR3024064T3 (en) 1997-10-31
HK1006412A1 (en) 1999-02-26
JPH1081625A (ja) 1998-03-31
DK0536282T3 (da) 1997-10-27
EP0536282A4 (en) 1993-05-05
JP2007063296A (ja) 2007-03-15
CA2084775C (en) 2003-04-15
EP0536282A1 (en) 1993-04-14
AU650033B2 (en) 1994-06-09
KR930701175A (ko) 1993-06-11
JP2002308776A (ja) 2002-10-23
US5496556A (en) 1996-03-05
US5300294A (en) 1994-04-05
IE912233A1 (en) 1992-01-01
ATE151635T1 (de) 1997-05-15
JP2702280B2 (ja) 1998-01-21
CA2084775A1 (en) 1991-12-28
ZA914919B (en) 1992-07-29
JP2000309536A (ja) 2000-11-07
DE69125714T2 (de) 1997-10-23
JPH05508155A (ja) 1993-11-18
AU8207691A (en) 1992-01-23
IE81134B1 (en) 2000-03-22
WO1992000010A1 (en) 1992-01-09

Similar Documents

Publication Publication Date Title
ES2100952T3 (es) Medicamento para tratar adenocarcinoma prostatico.
BR9807674A (pt) Inibidores bicìclicos da proteìna farnesil transferase
NO20044458L (no) Anvendelse av en ringsystemforbindelse for fremstilling av et medikament
CA1273019C (en) ENKEPHALINASE INHIBITORS
MX9304638A (es) Composicion para tratar e inhibir las ulceras gastricas y duodenales.
DK1203770T3 (da) Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af hyperplasi og andre sygdomme
SE8104624L (sv) Anvendning av kombinationen av en aromatashemmare med ett antindrogent medel for profylax och terapi av prostatahyperaplasi
BR9909961A (pt) Derivados de cadeia lateral alquila e alquenila funcionalizados de glicinamidas como inibidores de farnesil transferase
ES2150663T3 (es) Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina.
ATE191221T1 (de) Steroid-sulfatase hemmende verbindungen
PT981341E (pt) Uso de derivados de acido betulinico para o tratamento e prevencao de melanona
ES2118414T3 (es) Utilizacion de derivados del indolocarbazol para el tratamiento de la prostata.
NO961575D0 (no) 16-substituerte-4-aza-androstan 5 hibitorer
ES2156120T3 (es) Derivados arilamidicos.
MX9602861A (es) Mezcla estabilizante sinergistica.
ZW2282A1 (en) Tetrahydronaphthalene and indane derivatives
FI940731A0 (fi) Amiditetratsolit ACAT-inhibiitoreina
DE69634955D1 (de) Tripeptidylpeptidase-inhibitoren
ID26965A (id) Obat untuk mencegah dan/atau mengobati kanker payudara, yang mengandung inhibitor aromatase steroid
TW325997B (en) Pharmaceutical composition for preventing and treating retinal diseases
EA199800468A1 (ru) 25-гидрокси-16-ен-26,27-бисгомохолекальциферолы
ATE149840T1 (de) Behandlung von leberkrebs
FI953002A0 (fi) Menetelmä kroonisen eturauhastulehduksen hoitamiseksi 17beta-N-monosubstituoiduilla karbamoyyli-4-atsa-5alfa-androst-1-en-3-oneilla
AR247432A1 (es) Agente para la preparacion de fibras y procedimiento para su preparacion
AR005866A1 (es) Composicion farmaceutica antioxidante

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 536282

Country of ref document: ES